Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Barni

Showing results (301-310 of 369) with videos related to

Pageof 37
Sort By:
Advances in Experimental Medicine and Biology|January 1, 1993
Biochemical modulation of fluoropyrimidines: the "GISCAD" studies. GISCAD (Italian Group for the Study of Digestive Tract Cancer)R Labianca, G Pancera, S Barni, et al.
Cancer|March 15, 1993
In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2P Lissoni, S Pittalis, F Brivio, et al.
Tumori|October 31, 1987
Clinical study of melatonin in untreatable advanced cancer patientsP Lissoni, S Barni, G Tancini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1991
Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer)R Labianca, G Pancera, E Aitini, et al.
Oncology|January 1, 1992
Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatinP Lissoni, S Barni, A Ardizzoia, et al.
Archivio Italiano Di Urologia, Andrologia : Organo Ufficiale [Di] Societa Italiana Di Ecografia Urologica E Nefrologica|April 1, 1995
[Lymphocyte levels before treatment with subcutaneous interleukin-2 and during maintenance treatment in relation to the clinical efficacy in metastatic renal carcinoma]M G Viganò, P Lissoni, S Barni, et al.
Journal of Biological Regulators and Homeostatic Agents|October 1, 1995
Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II studyP Lissoni, L Vigorè, R Rescaldani, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinomaR Aldeghi, P Lissoni, S Barni, et al.
British Journal of Cancer|February 24, 2001
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancerS Cascinu, F Graziano, S Barni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2007
Agreement between oncology guidelines and clinical practice in Italy: the 'right' program. A project of the Italian Association of Medical Oncology (AIOM)S Barni, M Venturini, G D Beretta, et al.
Pageof 37

Showing results (301-310 of 369) with videos related to

Sort By:
Pageof 37
Advances in Experimental Medicine and Biology|January 1, 1993
Biochemical modulation of fluoropyrimidines: the "GISCAD" studies. GISCAD (Italian Group for the Study of Digestive Tract Cancer)R Labianca, G Pancera, S Barni, et al.
Cancer|March 15, 1993
In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2P Lissoni, S Pittalis, F Brivio, et al.
Tumori|October 31, 1987
Clinical study of melatonin in untreatable advanced cancer patientsP Lissoni, S Barni, G Tancini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1991
Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer)R Labianca, G Pancera, E Aitini, et al.
Oncology|January 1, 1992
Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatinP Lissoni, S Barni, A Ardizzoia, et al.
Archivio Italiano Di Urologia, Andrologia : Organo Ufficiale [Di] Societa Italiana Di Ecografia Urologica E Nefrologica|April 1, 1995
[Lymphocyte levels before treatment with subcutaneous interleukin-2 and during maintenance treatment in relation to the clinical efficacy in metastatic renal carcinoma]M G Viganò, P Lissoni, S Barni, et al.
Journal of Biological Regulators and Homeostatic Agents|October 1, 1995
Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II studyP Lissoni, L Vigorè, R Rescaldani, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinomaR Aldeghi, P Lissoni, S Barni, et al.
British Journal of Cancer|February 24, 2001
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancerS Cascinu, F Graziano, S Barni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2007
Agreement between oncology guidelines and clinical practice in Italy: the 'right' program. A project of the Italian Association of Medical Oncology (AIOM)S Barni, M Venturini, G D Beretta, et al.
Pageof 37